Topical Therapy of AD: How to Reach Better Results
AbstractPurpose of ReviewThis review summarizes the current state-of-the-art in topical therapy of atopic dermatitis (atopic eczema), a clinically defined, highly variable, pruritic chronic skin disease characterized by age-dependent distribution patterns and lesion morphology.Recent FindingsCurrent emollient treatment should be performed at least once daily, using about 250 g of emollient per week. Commonly used topical anti-inflammatory treatment is based on topical corticosteroids and the topical calcineurin inhibitors tacrolimus and pimecrolimus. Acute intervention for flares works best with topical corticosteroid cr...
Source: Current Dermatology Reports - April 22, 2017 Category: Dermatology Source Type: research
206 Racial/ethnic differences in healthcare utilization and school attendance among children with atopic dermatitis in the Pediatric Eczema Elective Registry
Little is known about healthcare utilization for atopic dermatitis (AD) and the impact of AD on school attendance especially among racial/ethnic minorities. We aimed to examine healthcare utilization and school missed due to AD by race/ethnicity among a cohort of U.S. children with AD. We performed a cross-sectional study of baseline data for children (ages 2-17) with physician-confirmed AD enrolled in the Pediatric Eczema Elective Registry (PEER; N=7,901). All subjects had to have used pimecrolimus cream for at least 6 weeks at the time of enrollment. (Source: Journal of Investigative Dermatology)
Source: Journal of Investigative Dermatology - April 12, 2017 Category: Dermatology Authors: J. Takeshita, J. Wan, N. Mitra, D.J. Margolis Tags: Clinical Research: Epidemiology of Skin Diseases Source Type: research
Dupilumab (Dupixent) for Moderate to Severe Atopic Dermatitis
Date: April 24, 2017
Issue #:
1519Summary:
The FDA has approved dupilumab (Dupixent– Sanofi/Regeneron), a subcutaneously-injected fully human
monoclonal antibody, for treatment of adults with
moderate to severe atopic dermatitis (eczema) that
has not responded to topical therapies. It can be used
with or without topical corticosteroids. (Source: The Medical Letter)
Source: The Medical Letter - March 22, 2017 Category: Drugs & Pharmacology Authors: admin Tags: Antibacterials Atopic dermatitis corticosteroids crisaborole Cyclosporine dupilumab Dupixent Elidel Eucrisa Phototherapy Pimecrolimus Protopic Tacrolimus Source Type: research
Comparison of different regimens of pimecrolimus 1% cream in the treatment of facial seborrheic dermatitis
ConclusionWe recommend pimecrolimus 1% cream could be applied twice a day for 4 weeks to treat seborrheic dermatitis. (Source: Journal of Cosmetic Dermatology)
Source: Journal of Cosmetic Dermatology - March 1, 2017 Category: Dermatology Authors: Juemin Zhao, Wenjia Sun, Chengfeng Zhang, Jiaqiang Wu, Yan Le, Chunyun Huang, Ye Liu, Leihong Xiang Tags: ORIGINAL CONTRIBUTION Source Type: research
Molecular signatures order the potency of topically applied anti-inflammatory drugs in atopic dermatitis patients
Our novel intra-patient evaluation of topical formulations found pronounced differences in biomarker responses between steroids, pimecrolimus, and emollient. While clinical and mechanistic data were congruent, the tissue analyses provided higher differentiation between various products. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 23, 2017 Category: Allergy & Immunology Authors: Emma Guttman-Yassky, Benjamin Ungar, Kunal Malik, Daniel Dickstein, Maria Suprun, Yeriel D. Estrada, Hui Xu, Xiangyu Peng, Margeaux Oliva, Dan Todd, Tord Labuda, Mayte Suarez-Farinas, Robert Bissonnette Source Type: research
Violaceous papules and plaques associated with Crohn's disease
A 25-year-old woman with Crohn's disease that was well controlled with infliximab presented with a 10-month history of violaceous plaques. Physical examination revealed multiple red to violaceous papules and plaques on the extensor surfaces of her elbows, knees, toes, fingers, and dorsal aspects of her feet (Fig 1). She denied fever, arthralgias, pain, or other systemic symptoms. The skin lesions had been unsuccessfully treated with oral prednisone, intralesional triamcinolone, topical clobetasol, and pimecrolimus. (Source: Journal of the American Academy of Dermatology)
Source: Journal of the American Academy of Dermatology - December 14, 2016 Category: Dermatology Authors: Cristian D. Gonzalez, Jason E. Hawkes, Marta J. Petersen Tags: JAAD Online Source Type: research
Topical Treatment of Facial Seborrheic Dermatitis: A Systematic Review
ConclusionPromiseb®, desonide, mometasone furoate, and pimecrolimus were found to be effective topical treatments for facial SD, as they had the lowest recurrence rate, highest clearance rate, and the lowest severity scores (e.g., erythema, scaling, and pruritus), respectively. Ciclopirox olamine, ketoconazole, lithium (gluconate and succinate), and tacrolimus are also strongly recommended (level A recommendations) topical treatments for facial SD, as they are consistently effective across high-quality trials (randomized controlled trials). (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - November 1, 2016 Category: Dermatology Source Type: research
Annular Lichenoid Dermatitis of Youth: A Chronic Case Managed Using Pimecrolimus
We report a case of annular lichenoid dermatitis of youth relapsing over the course of 5 years successfully treated and maintained with topical pimecrolimus cream. (Source: Pediatric Dermatology)
Source: Pediatric Dermatology - September 21, 2016 Category: Dermatology Authors: Stephen J. Malachowski, Mackenzie Creasey, Nancy Kinkley, Michael R. Heaphy Tags: Brief Report Source Type: research
Impact of Measuring Patient-Reported Outcomes in Dermatology Drug Development
AbstractAlthough some symptoms of dermatologic diseases, such as pruritus and pain, can be subjectively assessed only by patients, the most commonly used endpoints in dermatology drug research traditionally have been clinician-reported outcomes. Research has found that patient-reported outcomes (PROs) were included in only one-quarter of 125 trials conducted between 1994 and 2001. Our objective was to characterize the impact of PROs in dermatology drug development from the patient, prescriber, regulator, payer, and manufacturer perspectives using a case study approach. We conducted a structured literature review for pivota...
Source: The Patient - Patient-Centered Outcomes Research - September 14, 2016 Category: Global & Universal Source Type: research
Pharmacologic Treatment of Vitiligo in Children and Adolescents: A Systematic Review
ConclusionsThe main outcome measurements were morphometric analysis performed using a computer program, hematologic or biochemical change, and photography (predominant). It is unclear which was the most effective treatment for vitiligo, however, it was found that these therapies are all promising in the treatment of the disease. With proper care, disease control and repigmentation, even if partial, can be achieved. (Source: Pediatric Dermatology)
Source: Pediatric Dermatology - August 31, 2016 Category: Dermatology Authors: Andreia Freire Menezes, Fernanda Oliveira de Carvalho, Rosana S. S. Barreto, Bruno Santana Silva, Saravanan Shanmugam, Ricardo Queiroz Gurgel, Adriano Antunes Souza Ara újo Tags: Review Source Type: research
Review on Tinea Incognita
Abstract
Tinea incognito is a superficial dermatophytosis that clinically has been modified by misuse and misadministration of corticosteroids, topical or systemic, and less frequently by immunomodulators such as pimecrolimus, either by auto-medication or prescription. As a consequence, the dermatophytosis has an atypical clinical presentation, without the classic signs that orient us to a prompt diagnosis. In these cases, the mycosis may clinically mimic other skin diseases, or may superimpose on a previous dermatosis, usually an inflammatory one. The diagnosis and treatment are the same as for any other...
Source: Current Fungal Infection Reports - July 4, 2016 Category: Infectious Diseases Source Type: research
Study of the Atopic March: Development of Atopic Comorbidities
ConclusionsThis longitudinal observation of infants with AD provides evidence of the atopic march. Pimecrolimus was safe and effective in infants with mild to moderate AD. (Source: Pediatric Dermatology)
Source: Pediatric Dermatology - April 30, 2016 Category: Dermatology Authors: Lynda Schneider, Jon Hanifin, Mark Boguniewicz, Lawrence F. Eichenfield, Jonathan M. Spergel, Rada Dakovic, Amy S. Paller Tags: Original Article Source Type: research
544 A model to evaluate intra-patient differential effects of topical agents in atopic dermatitis
Atopic dermatitis/AD is the most common inflammatory skin disease, with a large unmet need for topical treatments with better efficacy and without long-term side effects associated with topical steroids or calcineurin antagonists. In psoriasis, the plaque test model is valuable for evaluating topical formulations, but has not been evaluated in AD, in which lesions are less stable. To evaluate a novel approach in AD that compares topical agents, we enrolled 30 mild-to-moderate AD patients in a phase I, randomized, vehicle-controlled, double-blinded, intra-individual comparison trial of 3 agents applied daily for 15d: Elidel...
Source: Journal of Investigative Dermatology - April 20, 2016 Category: Dermatology Authors: E. Guttman-Yassky, M. Suarez-Farinas, B. Ungar, M. Oliva, M. Suprun, D. Todd, T. Labuda, R. Bissonnette Tags: Pharmacology & Drug Development Source Type: research
Topical Therapies for Psoriasis: Improving Management Strategies and Patient Adherence.
Authors: Stein Gold LF
Abstract
Psoriasis is a chronic disease that has a substantial effect on quality of life of patients and often needs long-term treatment. Topical treatments for psoriasis include corticosteroids, vitamin D derivatives, tazarotene, anthralin, tacrolimus, pimecrolimus, and newer formulations of tar. Although many of these treatments are effective, they must be prescribed appropriately and used consistently for a period of weeks to months before clinical evidence of improvement can be seen and patients perceive that the treatment is working. As such, medication dosage/schedule, choice o...
Source: Seminars in Cutaneous Medicine and Surgery - April 15, 2016 Category: Dermatology Tags: Semin Cutan Med Surg Source Type: research
